

- **Name:** Sun Min Lim
  - **Current Position & Affiliation:** Assistant Professor, Yonsei Cancer Center, Yonsei University
  - **Country:** Korea
- 

**• Educational Background:**

- 2002.3 ~ 2008.2 College of Medicine, Yonsei University, Seoul, Republic of Korea
- 2006.1 ~ 2006.2 Washington University School of Medicine, St Louis, Missouri (Visiting student)
- 2010.9 ~ 2017.2 Master's Degree/Doctor of Philosophy, Yonsei University Graduate School

**• Professional Experience:**

- 2008.3 ~ 2009.2 Internship, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
- 2009.3 ~ 2013.2 Residency in Internal Medicine. Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
- 2012.3~ 2013.2 Chief medical resident, Department of Internal medicine, Severance Hospital
- 2013.3~2015.8 Fellow, Division of Medical Oncology, Department of Internal Medicine, Severance Hospital
- 2015.9~2020.2 Assistant Professor, CHA Bundang Medical Center, CHA University
- 2020.3~Present Assistant Professor, Yonsei University College of Medicine

**• Professional Organizations:**

- 2012~ Member, American Society of Clinical Oncology
- 2012~ Member, American Association of Cancer Research
- 2012~ Member, Korean Association for Clinical Oncology
- 2012~ Member, Korean Cancer Study Group
- 2013~ Member, International Association for the Study of Lung Cancer

**• Main Scientific Publications:**

1. **Lim SM**, Kim HR, Lee JS, et al. An open-label, multicenter, phase II study of

- ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. *J Clin Oncol* 2017;35(23):2613-2618.
2. Pyo KH, **Lim SM**, Kim HR, et al. Establishment of a conditional transgenic mouse model recapitulating EML4-ALK-positive human non-small-cell lung cancer. *J Thorac Oncol* 2017;12(3):491-500.(Co-first authors)
  3. Yun MR, **Lim SM**, et al. Enhancer remodeling and microRNA alterations are associated with acquired resistance to ALK inhibitors. *Cancer Res* 2018; 78(12):3350-3362. (Co-first authors)
  4. **Lim SM**, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. *Cancer Treat Rev* 2018; 65: 1-10.
  5. Yang Y-M, Jang Y, Lee SH, Kang B, **Lim SM**. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation. *Lung Cancer* 2020; 146:70-77.